Advertisement

Registries and Collaborative Groups in Peritoneal Surface Oncology

  • Aditi Bhatt
  • Kiran K. Turaga
Chapter

Abstract

Collaborative efforts of surgeons treating peritoneal metastases led to multi-institutional studies that generated evidence for treating PM where clinical trials are lacking. Registries represent an organized way of data collection and storage and collect the real-world experience about what is happening in clinical practice. These data systems generally define a specific data dictionary that then leads to uniform data collection and data transformation about predisposing factors, diagnosis, and therapies related to peritoneal surface malignancies. These are useful adjuncts to multi-institutional randomized trials, large observational studies, and single-institution studies that yield level II clinical evidence. The aspects of therapy that cannot be evaluated in clinical trials can be studied from the data provided by registries. Despite certain limitations like bias in recruiting patients, registries have been and will continue to be an important source of clinical evidence. Effective collaboration between clinicians of various specialities is required to successfully run such programs especially in countries where there are no regulatory norms. The information derived from clinical practice is as important for research as the information derived from preclinical and clinical studies, and resources should be invested in capturing this information adequately. Multi-institutional registries are an ideal tool for capturing this information.

Keywords

Peritoneal surface malignancies Registries HIPEC registry 

References

  1. 1.
    Bartlett DL. HIPEC: the complexities of clinical trials. Ann Surg Oncol. 2008;15(5):1277–9.  https://doi.org/10.1245/s10434-007-9768-y.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Glehen O, Mohamed F, Gilly FN. Digestive peritoneal carcinomatosis: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol. 2004;5:219–28.CrossRefPubMedGoogle Scholar
  3. 3.
    Gilly FN, Carry PY, Sayag AC, et al. Regional chemotherapy (with mitomycin C) and intra-operative hyperthermia for digestive cancers with peritoneal carcinomatosis. Hepatogastroenterology. 1994;41:124–9.PubMedGoogle Scholar
  4. 4.
    Glehen O, Kwiatkowski F, Sugarbaker PH, et al. Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol. 2004;22:3284–92.CrossRefPubMedGoogle Scholar
  5. 5.
    Glehen O, Gilly FN, Boutitie F, Bereder JM, Quenet F, Sideris L, Mansvelt B, Lorimier G, Msika S, Elias D. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Cancer. 2010;116:5608–18.  https://doi.org/10.1002/cncr.25356.CrossRefPubMedGoogle Scholar
  6. 6.
    Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, Gutman M, Tentes AA, Lorimier G, Bernard JL, Bereder JM, Porcheron J, Gomez-Portilla A, Shen P, Deraco M, Rat P. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for colorectal carcinomatosis: a multi-institutional registry of 506 patients. J Clin Oncol. 2004;22:3284–92.CrossRefPubMedGoogle Scholar
  7. 7.
    Verwaal VJ, van Ruth S, de Bree E, et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43.CrossRefPubMedGoogle Scholar
  8. 8.
    Verwaal VJ, Bruin S, Boot H, et al. 8-Year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol. 2008;15(9):2426–32.CrossRefPubMedGoogle Scholar
  9. 9.
    Spilliotis J, Halkia E, Lianos E, et al. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22(5):1570–5.CrossRefGoogle Scholar
  10. 10.
    Gouy S, Ferron G, Glehen O, Bayar A, Marchal F, Pomel C, Quenet F, Bereder JM, Le Deley MC, Morice P. Results of a multicenter phase I dose-finding trial of hyperthermic intraperitoneal cisplatin after neoadjuvant chemotherapy and complete cytoreductive surgery and followed by maintenance bevacizumab in initially unresectable ovarian cancer. Gynecol Oncol. 2016;142(2):237–42.  https://doi.org/10.1016/j.ygyno.2016.05.032. Epub 2016 Jun 2CrossRefPubMedGoogle Scholar
  11. 11.
    Zivanovic O, Abramian A, Kullmann M, Fuhrmann C, Coch C, Hoeller T, Ruehs H, Keyver-Paik MD, Rudlowski C, Weber S, Kiefer N, Poelcher ML, Thiesler T, Rostamzadeh B, Mallmann M, Schaefer N, Permantier M, Latten S, Kalff J, Thomale J, Jaehde U, Kuhn WC. HIPEC ROC I: a phase 1 study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer. Int J Cancer. 2015;136:699–708.  https://doi.org/10.1002/ijc.29011.PubMedGoogle Scholar
  12. 12.
    Ji ZH, Peng KW, Yu Y, Li XB, Yonemura Y, Liu Y, Sugarbaker PH, Li Y. Current status and future prospects of clinical trials on CRS + HIPEC for gastric cancer peritoneal metastases. Int J Hyperthermia. 2017;26:1–33.  https://doi.org/10.1080/02656736.2017.1283065. Epub ahead of printGoogle Scholar
  13. 13.
    Cowan RA, O'Cearbhaill RE, Zivanovic O, Chi DS. Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer. Int J Hyperthermia. 2017;16:1–21.  https://doi.org/10.1080/02656736.2017.1283066.Google Scholar
  14. 14.
    Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, Baratti D, Deraco M, Elias D, Sardi A, Liauw W, Yan TD, Barrios P, Gómez Portilla A, de Hingh IH, Ceelen WP, Pelz JO, Piso P, González-Moreno S, Van Der Speeten K, Morris DL. Early- and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449–56.CrossRefPubMedGoogle Scholar
  15. 15.
    Elias D, Gilly F, Boutitie F, et al. Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study. J Clin Oncol. 2010;28:63–8.  https://doi.org/10.1200/JCO.2009.23.9285.CrossRefPubMedGoogle Scholar
  16. 16.
    Franko J, Shi Q, Goldman CD, et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol. 2012;30:263–7.  https://doi.org/10.1200/JCO.2011.37.1039.CrossRefPubMedGoogle Scholar
  17. 17.
    Klaver YLB, Simkens LHJ, Lemmens VEPP, et al. Outcomes of colorectal cancer patients with peritoneal carcinomatosis treated with chemotherapy with and without targeted therapy. Eur J Surg Oncol. 2012;38:617–23.  https://doi.org/10.1016/j.ejso.2012.03.008.CrossRefPubMedGoogle Scholar
  18. 18.
    Koopman M, Antonini NF, Douma J, et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet. 2007;370:135–42.  https://doi.org/10.1016/S0140-6736(07)61086-1.CrossRefPubMedGoogle Scholar
  19. 19.
    Villeneuve L, Isaac S, Glehen O, Capovilla M, Chevallier A, Croce S, et al. The RENAPE network: towards a new healthcare organization for the treatment of rare tumors of the peritoneum. Description of the network and role of the pathologists. Ann Pathol. 2014;34(1):4–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Pelz J. Peritoneal carcinomatosis: registry and centers in Germany. Viszeralmedizin. 2013;29:226–9.CrossRefGoogle Scholar
  21. 21.
    Bhatt A, Mehta S, Ramakrishnan AS, et al. Indian HIPEC registry - a registry for Indian patients with peritoneal surface malignancies. J Peritoneum. 2016;1(1):107–8.Google Scholar
  22. 22.
    Webster’s English Dictionary. http://www.m-w.com. Accessed 16 May 2017
  23. 23.
    Razenberg LG, van Gestel YR, Lemmens VE, de Wilt JH, Creemers GJ, de Hingh IH. The prognostic relevance of histological subtype in patients with peritoneal metastases from colorectal cancer: a nationwide population-based study. Clin Colorectal Cancer. 2015;14(4):e13–9.  https://doi.org/10.1016/j.clcc.2015.05.011. Epub 2015 Jun 6CrossRefPubMedGoogle Scholar
  24. 24.
    Seyfried F, von Rahden BH, Miras AD, et al. Incidence, time course and independent risk factors for metachronous peritoneal carcinomatosis of gastric origin – a longitudinal experience from a prospectively collected database of 1108 patients. BMC Cancer. 2015;15:73.  https://doi.org/10.1186/s12885-015-1081-8.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Dreyer NA, Garner S. Registries for robust evidence. JAMA. 2009;302(7):790–1.CrossRefPubMedGoogle Scholar
  26. 26.
    Glicklich RE, Dreyer N. Registries for evaluating patient outcomes: a user’s guide, <http://effectivehealthcare.ahrq.gov/index.cfm/search-for-guides-reviews-and-reports/?productid=12&pageaction=displayproduct> (2017).
  27. 27.
  28. 28.
    Gilly FN, International Registry of Colorectal Carcinomatosis. Phase II studies: international registry of colorectal carcinomatosis. Eur J Surg Oncol. 2006;32(6):648–54. Epub 2006 May 5CrossRefPubMedGoogle Scholar
  29. 29.
    Lakshmaiah KC, Guruprasad B, Lokesh KN, Veena VS. Cancer notification in India. South Asian J Cancer. 2014;3(1):74–7.  https://doi.org/10.4103/2278-330X.126542.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Van Oudheusden TR, Razenberg LG, van Gestel YR, Creemers GJ, Lemmens VE, de Hingh IH. Systemic treatment of patients with metachronous peritoneal carcinomatosis of colorectal origin. Sci Rep. 2015;5:18632.  https://doi.org/10.1038/srep18632.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Gershenson DM, Bodurka DC, Lu KH, et al. Impact of age and primary disease site on outcome in women with low-grade serous carcinoma of the ovary or peritoneum: results of a large single-institution registry of a rare tumor. J Clin Oncol. 2015;33(24):2675–82.  https://doi.org/10.1200/JCO.2015.61.0873.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Quere P, Facy O, Manfredi S, Jooste V, Faivre J, Lepage C, Bouvier AM. Epidemiology, management, and survival of peritoneal carcinomatosis from colorectal cancer: a population-based study. Dis Colon Rectum. 2015;58(8):743–52.  https://doi.org/10.1097/DCR.0000000000000412.CrossRefPubMedGoogle Scholar
  33. 33.
    Dahm-Kähler P, et al. Population-based study of survival for women with serous cancer of the ovary, fallopian tube, peritoneum or undesignated origin - on behalf of the Swedish gynecological cancer group (SweGCG). Gynecol Oncol. 144(1):167–73.Google Scholar
  34. 34.
    Watanabe T, Muro K, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2017.  https://doi.org/10.1007/s10147-017-1101-6. Epub ahead of print
  35. 35.
    Classe JM, Glehen O, Decullier E, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for first relapse of ovarian cancer. Anticancer Res. 2015;35(9):4997–5005.PubMedGoogle Scholar
  36. 36.
    Maillet M, Glehen O, Lambert J, Goere D, Pocard M, Msika S, Passot G, Elias D, Eveno C, Sabaté JM, Lourenco N, André T, Gornet JM, BIG-RENAPE Working Group. Early postoperative chemotherapy after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for isolated peritoneal carcinomatosis of colon cancer: a multicenter study. Ann Surg Oncol. 2016;23(3):863–9.  https://doi.org/10.1245/s10434-015-4914-4. Epub 2015 Oct 19CrossRefPubMedGoogle Scholar
  37. 37.
    Helm CW, Richard SD, Pan J, Bartlett D, Goodman MD, Hoefer R, Lentz SS, Levine EA, Loggie BW, Metzinger DS, Miller B, Parker L, Spellman JE, Sugarbaker PH, Edwards RP, Rai SN. Hyperthermic intraperitoneal chemotherapy in ovarian cancer: first report of the HYPER-O registry. Int J Gynecol Cancer. 2010;20(1):61–9.  https://doi.org/10.1111/IGC.0b013e3181c50cde.CrossRefPubMedGoogle Scholar
  38. 38.
    Honoré C, Goéré D, Macovei R, Colace L, Benhaim L, Elias D. Peritoneal carcinomatosis from unusual cancer origins: is there a role for hyperthermic intraperitoneal chemotherapy? J Visc Surg. 2016;153(2):101–7.  https://doi.org/10.1016/j.jviscsurg.2015.11.010. Epub 2015 Dec 11CrossRefPubMedGoogle Scholar
  39. 39.
    Villeneuve L, Passot G, Glehen O, et al. The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry. Orphanet J Rare Dis. 2017;12:37.  https://doi.org/10.1186/s13023-017-0571-y.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Pelz JO. Peritoneal carcinomatosis: registry and centers in Germany. Viszeralmedizin. 2013;29:226–9.CrossRefGoogle Scholar
  41. 41.
    Verwaal V, Rau B, Jamali F, et al. Registries on peritoneal surface malignancies through out the world, their use and their options. Int J Hyperthermia. 2017.  https://doi.org/10.1080/02656736.2017.1315178.
  42. 42.
    Kusamura S, Baratti D, Hutanu I, Rossi P, Deraco M. The importance of the learning curve and surveillance of surgical performance in peritoneal surface malignancy programs. Surg Oncol Clin N Am. 2012;21(4):559–76.CrossRefPubMedGoogle Scholar
  43. 43.
    Kusamura S, Baratti D, Deraco M. Multidimensional analysis of the learning curve for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal surface malignancies. Ann Surg. 2012;255(2):348–56.CrossRefPubMedGoogle Scholar
  44. 44.
    Kuijpers AM, Hauptmann M, Aalbers AG, Nienhuijs SW, de Hingh IH, Wiezer MJ, et al. Cytoreduction and hyperthermic intraperitoneal chemotherapy: the learning curve reassessed. Eur J Surg Oncol. 2016;42(2):244–50.CrossRefPubMedGoogle Scholar
  45. 45.
    Kusamura S, Baratti D, Younan R, Deraco M. The Delphi approach to attain consensus in methodology of local regional therapy for peritoneal surface malignancy. J Surg Oncol. 2008;98:217–9.  https://doi.org/10.1002/jso.21059.CrossRefPubMedGoogle Scholar
  46. 46.
    Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359–74.CrossRefPubMedGoogle Scholar
  47. 47.
    Villeneuve L, Thivolet A, Bakrin N, et al. A new internet tool to report peritoneal malignancy extent. PeRitOneal malignancy stage evaluation (PROMISE) application. Eur J Surg Oncol. 2016;42:877–82.CrossRefPubMedGoogle Scholar
  48. 48.
    EURORDIS, NORD, CORD. Joint declaration of 10 key principles for rare disease patient registries. 2012.Google Scholar
  49. 49.
    Villeneuve L, Isaac S, Glehen O, Capovilla M, Chevallier A, Croce S, Dartigues P, Fontaine J, Kaci R, Lang-Averous G, Laverriere MH, Leroux-Broussier A, Mery E, Poizat F, Valmary-Degano S, Verriele-Beurrier V, Gilly FN, Bibeau F. The RENAPE network: towards a new healthcare organization for the treatment of rare tumors of the peritoneum. Description of the network and role of the pathologists. Ann Pathol. 2014;34(1):4–8.  https://doi.org/10.1016/j.annpat.2014.01.008. Epub 2014 Feb 20CrossRefPubMedGoogle Scholar
  50. 50.
    Biobank-based research on digestive peritoneal carcinomatosis (the BIG-RENAPE Biobank). J Peritoneum (and other serosal surfaces) 2016;1:12.  https://doi.org/10.4081/joper.2016.12
  51. 51.
    Chirac P, Maillet D, Lepretre F, et al. Genomic copy number alterations in 33 malignant peritoneal mesothelioma analyzed by comparative genomic hybridization array. Hum Pathol. 2016;55:72–82.CrossRefPubMedGoogle Scholar
  52. 52.
    Hommell-Fontaine J, Isaac S, Passot G, et al. Malignant peritoneal mesothelioma treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is GLUT1 expression a major prognostic factor? A preliminary study. Ann Surg Oncol. 2013;20:3892–8.CrossRefPubMedGoogle Scholar
  53. 53.
    Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. 2008;34:196–201.  https://doi.org/10.1016/j.ejso.2007.04.002.CrossRefPubMedGoogle Scholar
  54. 54.
    Thomassen I, van Gestel YR, van Ramshorst B, Luyer MD, Bosscha K, Nienhuijs SW, Lemmens VE, de Hingh IH. Peritoneal carcinomatosis of gastric origin: a population-based study on incidence, survival and risk factors. Int J Cancer. 2014;134:622–8.  https://doi.org/10.1002/ijc.28373.CrossRefPubMedGoogle Scholar
  55. 55.
    van Gestel YR, de Hingh IH, van Herk-Sukel MP, van Erning FN, Beerepoot LV, Wijsman JH, Slooter GD, Rutten HJ, Creemers GJ, Lemmens VE. Patterns of metachronous metastases after curative treatment of colorectal cancer. Cancer Epidemiol. 2014;38(4):448–54.  https://doi.org/10.1016/j.canep.2014.04.004. Epub 2014 May 17CrossRefPubMedGoogle Scholar
  56. 56.
    Thomassen I, van Gestel YR, Lemmens VE, de Hingh IH. Incidence, prognosis, and treatment options for patients with synchronous peritoneal carcinomatosis and liver metastases from colorectal origin. Dis Colon Rectum. 2013;56(12):1373–80.  https://doi.org/10.1097/DCR.0b013e3182a62d9d.CrossRefPubMedGoogle Scholar
  57. 57.
    Thomassen I, Verhoeven RH, van Gestel YR, van de Wouw AJ, Lemmens VE, de Hingh IH. Population-based incidence, treatment and survival of patients with peritoneal metastases of unknown origin. Eur J Cancer. 2014;50(1):50–6.  https://doi.org/10.1016/j.ejca.2013.08.009. Epub 2013 Sep 3CrossRefPubMedGoogle Scholar
  58. 58.
    Thomassen I, Lemmens VE, Nienhuijs SW, Luyer MD, Klaver YL, de Hingh IH. Incidence, prognosis, and possible treatment strategies of peritoneal carcinomatosis of pancreatic origin: a population-based study. Pancreas. 2013;42(1):72–5.  https://doi.org/10.1097/MPA.0b013e31825abf8c.CrossRefPubMedGoogle Scholar
  59. 59.
    Socialstyrelsen. Swedish Cancer Registry. http://www.socialstyrelsen.se/register/halsodataregister/cancerregistret/inenglish. Accessed 4 Oct 2011.Google Scholar
  60. 60.
    Segelman J, Singnomklao T, Hellborg H, Martling A. Differences in multidisciplinary team assessment and treatment between patients with stage IV colon and rectal cancer. Colorectal Dis. 2009;11:768–74.CrossRefPubMedGoogle Scholar
  61. 61.
    Segelman J, Granath F, Holm T, Machado M, Mahteme H, Martling A. Incidence, prevalence and risk factors for peritoneal carcinomatosis from colorectal cancer. Br J Surg. 2012;99(5):699–705.  https://doi.org/10.1002/bjs.8679. Epub 2012 Jan 27CrossRefPubMedGoogle Scholar
  62. 62.
    Ardighieri L, Zeppernick F, Hannibal CG, et al. Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants. J Pathol. 2014;232(1):16–22.  https://doi.org/10.1002/path.4293.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Yan TD, Deraco M, Baratti D, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol. 2009;27:6237–42.  https://doi.org/10.1200/JCO.2009.23.9640.CrossRefPubMedGoogle Scholar
  64. 64.
    Glehen O, Gilly FN, Arvieux C, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(9):2370–7.CrossRefPubMedGoogle Scholar
  65. 65.
    Chia CS, You B, Decullier E, et al. Patients with peritoneal carcinomatosis from gastric cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: is cure a possibility? Ann Surg Oncol. 2016;23:1971.  https://doi.org/10.1245/s10434-015-5081-3.CrossRefPubMedGoogle Scholar
  66. 66.
    Chua TC, Yan TD, Deraco M, Glehen O, Moran BJ, Sugarbaker PH, Peritoneal Surface Oncology Group. Multi-institutional experience of diffuse intra-abdominal multicystic peritoneal mesothelioma. Br J Surg. 2011;98(1):60–4.  https://doi.org/10.1002/bjs.7263. Epub 2010 Sep 24CrossRefPubMedGoogle Scholar
  67. 67.
    Bakrin N, Gilly FN, Baratti D, et al. Primary peritoneal serous carcinoma treated by cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. A multi-institutional study of 36 patients. Eur J Surg Oncol. 2013;39:742–7.  https://doi.org/10.1016/j.ejso.2013.02.018.CrossRefPubMedGoogle Scholar
  68. 68.
    Classe JM, Glehen O, Decullier E, Bereder JM, Msika S, Lorimier G, Abboud K, Meeus P, Ferron G, Quenet F, Marchal F, Gouy S, Pomel C, Pocard M, Guyon F, Bakrin N, French Oncologic and Gynecologic HIPEC Group. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for first relapse of ovarian cancer. Anticancer Res. 2015;35(9):4997–5005.PubMedGoogle Scholar
  69. 69.
    Kepenekian V, Elias D, Passot G, et al. Diffuse malignant peritoneal mesothelioma: evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE database: multi-institutional retrospective study. Eur J Cancer. 2016;65:69–79.  https://doi.org/10.1016/j.ejca.2016.06.002.CrossRefPubMedGoogle Scholar
  70. 70.
    Yan TD, Deraco M, Elias D, et al. A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*. Cancer. 2011;117:1855–63.  https://doi.org/10.1002/cncr.25640.CrossRefPubMedGoogle Scholar
  71. 71.
    Razenberg LG, van Gestel YR, Lemmens VE, de Hingh IH, Creemers GJ. Bevacizumab in addition to palliative chemotherapy for patients with peritoneal carcinomatosis of colorectal origin: a nationwide population-based study. Clin Colorectal Cancer. 2016;15(2):e41–6.  https://doi.org/10.1016/j.clcc.2015.12.006. Epub 2015 Dec 17CrossRefPubMedGoogle Scholar
  72. 72.
    Maillet M, Glehen O, Lambert J, Goere D, Pocard M, Msika S, Passot G, Elias D, Eveno C, Sabaté JM, Lourenco N, André T, Gornet JM, BIG-RENAPE Working Group. Early postoperative chemotherapy after complete cytoreduction and hyperthermic intraperitoneal chemotherapy for isolated peritoneal carcinomatosis of colon cancer: a multicenter study. Ann Surg Oncol. 2016;23(3):863–9.  https://doi.org/10.1245/s10434-015-4914-4. Epub 2015 Oct 19CrossRefPubMedGoogle Scholar
  73. 73.
    Esquivel J, Chua TC, Stojadinovic A, Melero JT, Levine EA, Gutman M, Howard R, Piso P, Nissan A, Gomez-Portilla A, Gonzalez-Bayon L, Gonzalez-Moreno S, Shen P, Stewart JH, Sugarbaker PH, Barone RM, Hoefer R, Morris DL, Sardi A, Sticca RP. Accuracy and clinical relevance of computed tomography scan interpretation of peritoneal cancer index in colorectal cancer peritoneal carcinomatosis: a multi-institutional study. J Surg Oncol. 2010;102(6):565–70.  https://doi.org/10.1002/jso.21601.CrossRefPubMedGoogle Scholar
  74. 74.
    Razenberg LG, van Gestel YR, Creemers GJ, Verwaal VJ, Lemmens VE, de Hingh IH. Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritonealcarcinomatosis of colorectal origin in the Netherlands. Eur J Surg Oncol. 2015;41(4):466–71.  https://doi.org/10.1016/j.ejso.2015.01.018. Epub 2015 Jan 29CrossRefPubMedGoogle Scholar
  75. 75.
    Alyami M, Lundberg P, Kepenekian V, Goéré D, Bereder JM, Msika S, Lorimier G, Quenet F, Ferron G, Thibaudeau E, Abboud K, Lo Dico R, Delroeux D, Brigand C, Arvieux C, Marchal F, Tuech JJ, Guilloit JM, Guyon F, Peyrat P, Pezet D, Ortega-Deballon P, Zinzindohoue F, de Chaisemartin C, Kianmanesh R, Glehen O, Passot G, BIG-RENAPE and RENAPE Working Groups. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinomatosis in the elderly: a case-controlled, multicenter study. Ann Surg Oncol. 2016;23(Suppl 5):737–45. Epub 2016 Sep 6CrossRefPubMedGoogle Scholar
  76. 76.
    Charrier T, Passot G, Peron J, Maurice C, Gocevska S, Quénet F, Eveno C, Pocard M, Goere D, Elias D, Ortega-Deballon P, Vaudoyer D, Cotte E, Glehen O. Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy with oxaliplatin increases the risk of postoperative hemorrhagic complications: analysis of predictive factors. Ann Surg Oncol. 2016;23(7):2315–22.  https://doi.org/10.1245/s10434-016-5143-1. Epub 2016 Feb 26CrossRefPubMedGoogle Scholar
  77. 77.
    Voron T, Messager M, Duhamel A, Lefevre J, Mabrut JY, Goere D, Meunier B, Brigand C, Hamy A, Glehen O, Mariette C, Paye F. Is signet-ring cell carcinoma a specific entity among gastric cancers? Gastric Cancer. 2016;19(4):1027–40.  https://doi.org/10.1007/s10120-015-0564-2. Epub 2015 Nov 25CrossRefPubMedGoogle Scholar
  78. 78.
    Prada-Villaverde A, Esquivel J, Lowy AM, Markman M, Chua T, Pelz J, Baratti D, Baumgartner JM, Berri R, Bretcha-Boix P, Deraco M, Flores-Ayala G, Glehen O, Gomez-Portilla A, González-Moreno S, Goodman M, Halkia E, Kusamura S, Moller M, Passot G, Pocard M, Salti G, Sardi A, Senthil M, Spiliotis J, Torres-Melero J, Turaga K, Trout R. The American Society of Peritoneal Surface Malignancies evaluation of HIPEC with Mitomycin C versus Oxaliplatin in 539 patients with colon cancer undergoing a complete cytoreductive surgery. J Surg Oncol. 2014;110(7):779–85.  https://doi.org/10.1002/jso.23728. Epub 2014 Aug 2CrossRefPubMedGoogle Scholar
  79. 79.
    Vlaeminck-Guillem V, Bienvenu J, Isaac S, Grangier B, Golfier F, Passot G, Bakrin N, Rodriguez-Lafrasse C, Gilly FN, Glehen O. Intraperitoneal cytokine level in patients with peritoneal surface malignancies. A study of the RENAPE (French Network for Rare Peritoneal Malignancies). Ann Surg Oncol. 2013;20(8):2655–62.  https://doi.org/10.1245/s10434-013-2933-6. Epub 2013 Mar 22CrossRefPubMedGoogle Scholar
  80. 80.
    Ortega-Deballon P, Glehen O, Levine E, et al. Childbearing after hyperthermic intraperitoneal chemotherapy: results from an international survey. Ann Surg Oncol. 2011;18(8):2297–301.  https://doi.org/10.1245/s10434-011-1595-5.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Ferron G, Simon L, Guyon F, et al. Professional risks when carrying out cytoreductive surgery for peritoneal malignancy with hyperthermic intraperitoneal chemotherapy (HIPEC): a French multicentric survey. Eur J Surg Oncol. 2015;41(10):1361–7.  https://doi.org/10.1016/j.ejso.2015.07.012. Epub 2015 Jul 29CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of Surgical OncologyFortis HospitalBangaloreIndia
  2. 2.Department of Surgical OncologyUniversity of Chicago MedicineChicagoUSA

Personalised recommendations